Fig. 1

Objective response and PFS. The censored patient did not receive ENT 3 times during Cycle 2 (after the end of the DLT observation period), thereby meeting one of the criteria for discontinuation, namely that patients who did not take ENT three times within one cycle, or who did not take ENT three times in a row regardless of cycle, should be discontinued. The patient then started post-discontinuation treatment before diagnostic imaging was performed to assess possible progression. Therefore, we censored the patient at the time of the previous imaging at study entry. BOR best overall response, DLT dose-limiting toxicity, ENT entinostat, NE not evaluable, PD progressive disease, PFS progression-free survival, SD stable disease